Amaryl®
Glimepiride is an orally active hypoglycaemic substance belonging to the sulfonylurea group. It may be used in non-insulin dependent diabetes mellitus.
Apidra®
Insulin Glulisine, a fast-acting insulin administered subcutaneously used for treatment of adults, adolescents and children 6 years or older, with diabetes mellitus, where treatment with insulin is required.
Aprovel®
Irbesartan is a potent, orally active, selective angiotensin-II receptor (type AT1) antagonist. It is expected to block all actions of angiotensin-II mediated by the AT1 receptor, regardless of the source or route of synthesis of angiotensin-II used to Effectively control Hypertension to normal Rates.
Aubagio®
AUBAGIO® is a once-daily oral tablet that is indicated for adult patients with relapsing remitting multiple sclerosis (RRMS)
Clexane®
Enoxaparin Sodium is a low molecular weight heparin (LMWH) that is administered subcutaneously and used as antithrombotic agent.
Depakine®
Dupixent®
Is a fully human monoclonal antibody with multiple indications in different therapeutic areas.
Lantus®
Insulin Glargine 100, a long-acting insulin administered subcutaneously and used to treat diabetes mellitus in adults, adolescents and children from the age of 2 years.
Lemtrada®
Lemtrada® is a monoclonal antibody produced in mammalian cells (Chinese Hamster Ovary).
Plavix®
Clopidogrel is an inhibitor of platelet aggregation administered orally and indicated for Secondary prevention of atherothrombotic events.
Soliqua®
Combination of Insulin Glargine (a basal insulin analog) & Lixisenatide (a GLP-1 receptor agonist) administered subcutaneously.
Tavanic®
Levofloxacin is used in adults for the treatment of infections. The dosage depends on the type and severity of the infection and the susceptibility of the presumed causative pathogen.
Toujeo®
Insulin Glargine 300, a long-acting insulin administered subcutaneously and used to treat diabetes mellitus in adults, adolescents and children from the age of 6 years.
▼ This drug is subject to additional monitoring, the reporting of suspected adverse reactions associated with this drug is a priority.